Track record · closed signal

Stoke Therapeutics, Inc. (STOK) — closed signal from November 15, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on February 13, 2026.

Predicted vs. what happened

STOK price · publication thesis → realized outcomesplit-adjusted
$26.51 Published $33.14 Target $31.91 Window close $37.34 Peak
$26.00 – $26.75Entry zone — fair-value band
$26.51Published — price the day we called it
$33.14Target — the price the thesis aimed for
$37.34Peak — highest point inside the window, not a realized return
$31.91Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 23 days.

Peak price
$37.34
peak on January 7, 2026 — not a realized return
Peak gain
+40.9%
peak, from the publication price
Window close
$31.91
end-of-window price, context only
Days to target
23
Window
November 15, 2025 – February 13, 2026

The thesis — published November 15, 2025

Predicted growth
+25%
over the measurement window
Target price
$33.14
the price the thesis aimed for
Entry zone
$26.00 – $26.75
the fair-value band we waited for
Price at publication
$26.51
published November 15, 2025
Confidence
74%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Stoke is a smaller company where good news can move the stock more than usual, and its business outlook looks solid. Analysts recently turned more positive, with a Zacks Buy rating and H.C. Wainwright keeping a $35 goal, plus upbeat growth estimates. Price signs are still early, so start small and add only after strength is clear. In the next 3 months, trial updates could lift the stock, while timing and funding are key risks. Expect swings typical of biotech.

Primary drivers

  • Analysts turned more positive and raised their sales and earnings estimates
  • Investor mood is improving while the core business outlook looks solid
  • Recent news: Zacks Buy rating and H.C. Wainwright keeping a $35 target
  • Upcoming trial updates could shift how investors value the company

How it played out

STOK: target reached in 23 days

Lyra published STOK at 26.51 on 2025-11-15 with a short-term thesis for 25% growth. The thesis pointed to more positive analyst views, raised sales and earnings estimates, improving investor mood, a Zacks Buy rating, H.C. Wainwright keeping a $35 target, and possible trial updates inside the next 3 months. It also noted timing and funding risks.

Inside the window, the stock reached the 33.14 target in 23 days. It later peaked at 37.34 on 2026-01-07, a 40.9% gain. By 2026-02-13 it ended at 31.91. The published thesis played out.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All STOK signals